The Short discusses a 15% drop in Hims & Hers stock following an FDA announcement ending the shortage of Eli Lilly's weight loss drug, Zepibound (Trizepatide). Despite Hims & Hers not selling Trizepatide but offering semaglutide, which remains in shortage, investor confusion and overreaction led to the stock decline. The video suggests that this reaction doesn't reflect the company's fundamentals and some see it as a buying opportunity.
